Comparison of different pharmacodynamic models for pharmacokinetic- pharmacodynamic (PK-PD) modeling of carvedilol

Yaoxue Xuebao

Volumn 44, Issue 4, 2009, Pages 406-411

  Liu, Xiao Yan ^b   Wang, Ben Jie ^a   Yuan, Gui Yan ^a   Guo, Rui Chen ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Carvedilol; Effect compartment link model; Indirect response model; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CARVEDILOL;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTERIAL PRESSURE; ARTICLE; BIOLOGICAL MODEL; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IC 50; MALE; MANOMETRY;

ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CARBAZOLES; HUMANS; MALE; MODELS, CARDIOVASCULAR; PROPANOLAMINES;

EID: 64949090480     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Dulin B, Abraham WT. Phamacology of carvedilol [J]. Am J Cardiol, 2004, 93:3B-6B.
2. Honda M, Nozawa T, Igarashi N, et al. Effect of CYP2D6&z.ast;10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers [J]. Biol Pharm Bull, 2005, 28: 1476-1479.
3. Höcht C, DiVerniero C, Opezzo JAW, et al. Applicability of microdialysis as a technique for pharmacokinetic- pharmacrodynamic (PK-PD) modeling of antithypertensive beta-blockers [J]. J Pharmacol Toxicol Methods, 2005, 52: 244-250.
4. Hao K, Chen YC, Cao YG, et al. Pharmacokinetic- pharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats [J]. Acta Pharmacol Sin, 2007, 28: 738-743.
5. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives [J]. J Pharmacokinet Pharmacodyn, 2006, 33: 227-279.
6. Jeong DW, Kim YH, Ji HY, et al. Analysis of carvedilol in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry [J]. J Pharm Biomed Anal, 2007,44: 547-552.
7. Zarghi A, Foroutan SM, Shafaati A, et al. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies [J]. I Pharm Biomed Anal, 2007, 44:250-253.
8. Gu SF, Xiao Z, Dai ZS, et al. HPLC-fluorecence determination of carvedilol in human plasma and study on its pharmacokinetics [J]. J China Pharm Univ 2004, 35: 54-56.
9. Giessmann T, Modess C, Hecker U, et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects [J]. Clin Pharmacol Ther, 2004, 75: 213-222.
10. Tenero DM, Henderson LS, Campanile AM, et al. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta 1-blockade in patients with congestive heart failure [J]. Am J Cardiol, 2006, 98: 27L-31L.
11. Wu CX. Pharmacokinetic-pharmacodynamic modeling for antihypertensive effect of metoprolol [J]. J Med Forum, 2006, 27: 51-53.
12. Yin XX, Zhang YD. Pharmacokinetic-pharmacodynamic modeling of metoprolol enantiomers in the dog [J]. Acta Pharm Sin 1997, 32: 411-415.